- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Lepu Biopharma Co. Ltd.
Headquarters: Shanghai, China
Website: https://en.lepubiopharma.com/...
Year Founded: 2018
Status: Public
Industry Sector: HealthTechnology
CEO: Ziye Sui, PhD, MD
Number Of Employees: 498
Enterprise Value: $619,005,775
PE Ratio: -19.11
Exchange/Ticker 1: HKEX:2157
Exchange/Ticker 2: N/A
Latest Market Cap: $1,111,637,943
BioCentury | Jan 28, 2025
Deals
Abbvie seeks molecular glue degraders from Neomorph
Also in BioCentury’s Deals Report, Novo licenses BACH1 inhibitor from Immvention, Arrivent-Lepu in ADC deal, and Sage rejects Biogen’s bid
BioCentury | Jun 5, 2023
Product Development
ADCs help define AstraZeneca’s next oncology chapter
ASCO 2023 showcases data from TROP2 ADCs in non-small cell lung cancer and Enhertu in a tumor-agnostic trial
BioCentury | Mar 31, 2023
Deals
March 30 Quick Takes: Scynexis deal gives GSK another anti-infective
Plus: AstraZeneca in-licenses CLDN18.2 asset from China’s KYM, updates from newly public biotechs Apollomics and GI Innovation and more
BioCentury | Feb 24, 2023
Regulation
Feb. 23 Quick Takes: FDA approves Sanofi’s once-weekly hemophilia A therapy
Plus: CMS stays the course on Alzheimer's NCD and updates from Blueprint, Apellis, AZ, Nektar, Keymed, Prilenia and more
BioCentury | Jul 8, 2021
Finance
Keymed’s first-day valuation tops $2B after pricing Hong Kong IPO
Public investors welcomed Keymed with a warm reception on the Hong Kong stock exchange, signaling confidence in a pipeline that includes the Chinese biotech’s potential Dupixent competitor. In
Items per page:
1 - 5 of 5